Brittany Lovely

Managing Editor, OncLive®
Brittany Lovely is a managing editor for the OncologyLive® print publication and editor of the Miami Breast Cancer Conference® and Chemotherapy Foundation Symposium® dailies. Email: blovely@mjhassoc.com


Articles

DLL3-Targeting Agents Are Poised to Fill Unmet Needs in SCLC

October 18th 2023

Expression of DLL3, an inhibitor ligand of the Notch pathway associated with tumorigenesis, has emerged as a target of interest for drug development.

Frontline Osimertinib/Chemotherapy Combination Improves PFS in EGFR-Mutated NSCLC

September 11th 2023

Osimertinib in combination with platinum-based therapy and pemetrexed demonstrated a statistically significant and clinically meaningful improvement in progression-free survival vs osimertinib monotherapy in patients with EGFR-mutated advanced non–small cell lung cancer.

Sacituzumab Govitecan Plus Pembrolizumab Evokes Clinical Activity as Frontline Treatment for Metastatic NSCLC

September 10th 2023

Early antitumor activity has been observed in patients with metastatic non–small cell lung cancer treated with the combination of sacituzumab govitecan-hziy and pembrolizumab in the first-line setting.

Outcomes With Pediatric-Inspired Regimens Warrant Further Exploration in AYA PH- ALL

September 6th 2023

Varying outcomes were observed among adolescent and young adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia who were treated with pediatric-inspired protocols vs adult chemotherapy regimens.

Molecular Testing Drives Progress in CRC

July 31st 2023

Emerging strategies leveraging biomarker data for the treatment of patients with early-stage and metastatic colorectal cancer have made precision medicine a top-of-mind topic for gastrointestinal oncologists.

Birtamimab Pushes the Needle in AL Amyloidosis

July 26th 2023

Findings from an analysis of treatment patterns for patients with systemic amyloid light chain amyloidosis have demonstrated that several unmet needs exist, including timely diagnosis and limited survival outcomes for patients with advanced disease.

Geriatric Oncology ASCO Guidelines Provide Update on Importance of Assessment

July 25th 2023

ASCO has released an update to the guidelines for the practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy.

Prognostic Markers in Peripheral Blood Shine Light on Future Directions in NSCLC

July 16th 2023

Joseph Christopher Murray, MD, discusses the role of prognostic markers in non–small cell lung cancer and how data from the EMPOWER trials will guide future directions in the space.

Leveraging Biology to Guide First-Line Treatment of Clear Cell RCC

July 14th 2023

Determining the appropriate front-line treatment pathway for patients with clear cell renal cell carcinoma may not always align with risk stratification features.

Explorations Unearth New Potential of KRAS Mutations in Pancreatic Cancer

July 12th 2023

As more is understood about the biology of PDAC tumors, targeting common KRAS variants in these tumors following exhaustion of all curative intent surgery, chemotherapy, and radiation ushers in a novel postadjuvant setting for investigators.

Olaparib Bolsters Lutetium Lu 177 Vipivotide Tetraxetan Activity in mCRPC

July 11th 2023

Enhanced antitumor activity was shown with the addition of the PARP inhibitor olaparib to the radioligand lutetium Lu 177 vipivotide tetraxetan in patients with metastatic castration-resistant prostate cancer.

Fixed-Duration CAPTIVATE Regimen Is Effective in CLL Regardless of High-Risk Genomic Features

July 7th 2023

Treatment with fixed-duration ibrutinib plus venetoclax for patients with chronic lymphocytic leukemia in the first-line setting elicited durable responses and sustained progression-free survival outcomes regardless of high-risk genomic features.

Operational Innovations, AI to Play Vital Roles in EOM Data Collection

June 23rd 2023

The arrival of the Enhancing Oncology Model has renewed the uncertainties surrounding value-based care approaches for practices opting into the next wave of Center for Medicare & Medicaid Services performance structure

Optimizing Treatment Patterns in Relapsed or Refractory Differentiated Thyroid Cancer

June 21st 2023

A panel of head and neck cancer experts discussed the nuances of managing relapsed or refractory DTC with lenvatinib or sorafenib, as well as sequencing considerations with targeted therapies in the second-line setting and beyond for patients with relapsed or refractory disease.

Navtemadlin Elicits Spleen Volume Reduction When Added to Stable Ruxolitinib in Patients With Myleofibrosis

June 10th 2023

Patients with primary or secondary TP53 wild-type myelofibrosis who experienced suboptimal response to ruxolitinib had clinically meaningful improvements in spleen volume reduction with the addition of navtemadlin to ruxolitinib,

Erdafitinib Confers OS Benefit in FGFR-Altered Urothelial Cancer

June 5th 2023

Erdafitinib reduced the risk of death by 36% vs investigator’s choice of chemotherapy in patients with FGFR2/3-altered metastatic urothelial cancer who were previously treated with anti–PD-1 therapy, according to findings from the phase 3 THOR trial.

Trastuzumab Deruxtecan Elicits Promising Antitumor Activity in HER2+ mCRC

June 4th 2023

The 5.4-mg/kg dose of trastuzumab deruxtecan elicited numerically higher activity in patients with HER2-positive, metastatic colorectal cancer compared with the 6.4-mg/kg dose.

Efficacy of CLDN6-Directed CAR T Therapy Is Maintained With Automated Manufacturing in Solid Tumors

June 3rd 2023

When manufactured via automated process the CLDN6-directed CAR T-cell therapy, BNT211, demonstrated encouraging signs of activity and a manageable safety profile with or without the addition of CLDN6-encoding mRNA vaccine in patients with CLDN6-positive relapsed/refractory advanced solid tumors.

Efficacy and Safety of Abemaciclib Plus ET Is Maintained Older Patients with HR+, HER2–, Early Breast Cancer

June 3rd 2023

A clinically meaningful absolute risk reduction in invasive disease-free survival and distant relapse-free survival with abemaciclib plus endocrine therapy was maintained in patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer regardless of age.

Optimizing CSCC Management Requires a Multifaceted Approach to Care

May 17th 2023

Sunandana Chandra, MD, MS, Anna C. Pavlick, DO, MSc, MBA, BSN, and Nikhil Khushalani, MD, discuss the importance of multidisciplinary care in CSCC and patient counseling regarding available therapies.